Shares of DBV Technologies SA – (NASDAQ:DBVT) saw unusually-strong trading volume on Tuesday . Approximately 105,325 shares were traded during trading, an increase of 10% from the previous session’s volume of 95,498 shares.The stock last traded at $35.23 and had previously closed at $34.95.

A number of analysts have commented on DBVT shares. Leerink Swann reaffirmed a “buy” rating and set a $54.00 price target on shares of DBV Technologies SA – in a research report on Tuesday, August 23rd. Zacks Investment Research raised shares of DBV Technologies SA – from a “sell” rating to a “hold” rating in a research report on Wednesday, June 8th. Finally, Jefferies Group reissued a “buy” rating on shares of DBV Technologies SA – in a research report on Wednesday, June 8th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $50.27.

The firm’s market cap is $1.62 billion. The firm has a 50 day moving average price of $34.30 and a 200-day moving average price of $32.03.

An institutional investor recently raised its position in DBV Technologies SA – stock. RS Investment Management Co. LLC raised its position in DBV Technologies SA – (NASDAQ:DBVT) by 1.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 502,860 shares of the company’s stock after buying an additional 8,220 shares during the period. RS Investment Management Co. LLC owned 1.09% of DBV Technologies SA – worth $18,259,000 as of its most recent filing with the SEC.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.